NEUROPRO
OLIGOPEPTIDASE INHIBITORS IN BRAIN FUNCTION AND DYSFUNCTION: TOWARDS NEW THERAPEUTIC STRATEGIES FOR NEUROPROTECTION
| Coordinatore | KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Sito del progetto | http://www.neuropro.eu |
| Totale costo | 6˙290˙178 € |
| EC contributo | 4˙788˙220 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-10-01 - 2012-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | coordinator | 0.00 |
| 2 |
Nome Ente NON disponibile
Organization address
address: YLIOPISTONRANTA 1 E contact info |
FI (Kuopio) | participant | 0.00 |
| 3 |
CEREBRICON OY
Organization address
address: MICROKATU 1 contact info |
FI (KUOPIO) | participant | 0.00 |
| 4 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | participant | 0.00 |
| 5 |
MAGYAR TUDOMANYOS AKADEMIA SZEGEDI BIOLOGIAI KOZPONT ENZIMOLOGIAI INTEZET
Organization address
address: Karolina ut 29-31 contact info |
HU (BUDAPEST) | participant | 0.00 |
| 6 |
PEPSCAN PRESTO BV
Organization address
address: ZUIDERSLUISWEG 2 contact info |
NL (LELYSTAD) | participant | 0.00 |
| 7 |
PROBIODRUG AG
Organization address
address: WEINBERGWEG 22 contact info |
DE (HALLE) | participant | 0.00 |
| 8 |
RESEARCH CENTRE FOR NATURAL SCIENCES, HUNGARIAN ACADEMY OF SCIENCES
Organization address
address: PUSZTASZERI UTCA 59-67 contact info |
HU (BUDAPEST) | participant | 0.00 |
| 9 |
TARTU ULIKOOL
Organization address
address: ULIKOOLI 18 contact info |
EE (TARTU) | participant | 0.00 |
| 10 |
THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
UK (COVENTRY) | participant | 0.00 |
| 11 |
UNIVERSITAET LEIPZIG
Organization address
address: RITTERSTRASSE 26 contact info |
DE (LEIPZIG) | participant | 0.00 |
| 12 |
UNIVERSITEIT ANTWERPEN
Organization address
address: PRINSSTRAAT 13 contact info |
BE (ANTWERPEN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'At present more than 5 million people in the EU suffer from dementia and other neurodegenerative diseases and that number will grow as the average age of the population continues to increase. The efficacy of current medicines is limited and new therapeutic targets are sorely needed. Several independent lines of evidence have established an important role of prolyl oligopeptidase (PREP) in brain function and dysfunction. Aberrant PREP activity is involved in the progression of neurodegenerative disorders and PREP inhibitors are being developed for the treatment of memory and cognition deficits. Now a consortium of expert scientists from 8 academic institutes and 3 SME's come together for 4 years in this NEUROPRO project to boost European research aimed at 1) unravelling the biological role of PREP and PREP-like proteins in neuropathology, 2) determining the mode of action of PREP inhibitors and 3) firmly establishing their therapeutic potential. Specialists from different disciplines – cell and molecular biology, enzymology, chemistry, crystallography, biology and pharmacology – will work in a concerted and focussed way to achieve the goals using 6 work packages concentrating on PREP-regulated pathways in health and disease, PREP substrates, inhibitor target identification, drug development and validation, and generation of specific cell lines and animal models of neurodegenerative diseases. The SME’s involved are leaders in PREP inhibitor development and peptide analysis, and have in the past already brought novel therapeutics on the market. By the end of the project we expect to have proof of concept that PREP inhibition is a valid therapeutic target which will ultimately lead to new methods for the early detection, prevention or restoration of PREP-related neurodegeneration. The project also comprises instruments to translate basic research into clinical applications and will thus broaden the scope of treatments available to Europe's ageing population.'